• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Euthymics Bioscience

edit

Euthymics Bioscience, Inc. is a neuroscience-focused clinical-stage company developing next-generation treatments for depression. Euthymics’ initial focus is on patients who do not respond adequately to SSRIs. EB-1010 for depression is expected to improve efficacy and reduce the leading side effects associated with poor adherence to standard antidepressants including weight gain, sexual dysfunction and cognitive impairment. Euthymics is a private Delaware corporation with headquarters in Cambridge, Massachusetts.

Milestones

edit

• 
  Euthymics Bioscience added Thomas A. Shea as CFO.
  Posted 6/28/11 at 5:55pm
• 
  Euthymics Bioscience added Franklin P. Bymaster as Chief Scientific Officer, Co-Founder.
  Posted 7/23/10 at 6:33pm
• 
  Euthymics Bioscience added Anthony A. McKinney as President & CEO, Co-Founder.
  Posted 7/23/10 at 6:33pm
• 
  Euthymics Bioscience received $4M in Series A funding. (3/9/11)
  Posted 3/9/11 at 8:25pm via masshightech.com
• 
  Euthymics Bioscience received $24M in Series A funding. (7/22/10)
  Posted 7/23/10 at 6:33pm via euthymics.com
• 
  Euthymics Bioscience — added $4 million to its July, 2010, Series A financing round of $24 million, bringing the total raised by the company to $28 million (3/9/11)
  Posted 3/10/11 at 3:25am via masshightech.com

Videos

Screenshots

edit

Sources

1. EUTHYMICS BIOSCIENCE, INC. CLOSES $24 MILLION SERIES A FINANCING AND COMPLETES ACQUISITION OF DOV PHARMACEUTICAL (euthymics.com) [edit]
2. Euthymics Bioscience bumps Series A to $28M (masshightech.com) [edit]
Euthymics Bioscience bumps Series A to $28M (masshightech.com) [edit]